Tyr31
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr31  -  PXN iso2 (human)

Site Information
FLSEETPySyPTGNH   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448785
Associated spectra:  3 CST

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 41 ) , immunoprecipitation ( 4 , 27 ) , mass spectrometry ( 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 16 , 17 , 18 , 19 , 21 , 22 , 23 , 24 , 28 , 29 , 30 , 32 , 33 , 34 , 39 , 40 , 42 , 43 , 44 ) , microscopy-colocalization with upstream kinase ( 25 ) , mutation of modification site ( 1 , 4 , 25 , 27 , 35 , 37 , 41 ) , phospho-antibody ( 1 , 4 , 15 , 20 , 26 , 31 , 35 , 36 , 37 , 38 , 41 , 45 , 46 , 47 ) , western blotting ( 1 , 4 , 20 , 25 , 26 , 27 , 31 , 35 , 36 , 37 , 45 )
Disease tissue studied:
bile-duct cancer ( 13 ) , bone cancer ( 37 ) , osteosarcoma ( 37 ) , colorectal cancer ( 4 ) , colorectal carcinoma ( 4 ) , esophageal cancer ( 34 ) , gastric cancer ( 8 , 22 , 23 , 24 , 33 ) , gastric carcinoma ( 8 ) , liver cancer ( 9 , 12 , 14 ) , hepatocellular carcinoma ( 9 ) , lung cancer ( 8 , 21 , 28 , 29 , 30 , 45 ) , non-small cell lung cancer ( 21 , 28 , 29 , 30 ) , non-small cell lung adenocarcinoma ( 8 , 21 , 29 , 30 ) , non-small cell squamous cell lung carcinoma ( 8 ) , small-cell lung cancer ( 45 ) , lung cancer, surrounding tissue ( 2 ) , ovarian cancer ( 7 ) , pancreatic cancer ( 42 , 43 , 44 ) , prostate cancer ( 1 ) , melanoma skin cancer ( 11 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Treatments:
AG1478 ( 1 ) , androstanolone ( 1 ) , collagen_IV ( 38 ) , cyclic_stretch ( 26 ) , docetaxel ( 36 ) , EGF ( 41 ) , EphB1 ( 47 ) , fibronectin ( 45 ) , gefitinib ( 8 ) , HGF ( 15 ) , laulimalide ( 36 ) , Ox-PAPC ( 20 ) , PDGF ( 4 ) , PP2 ( 1 , 38 ) , PP3 ( 38 ) , Su11274 ( 8 ) , TIMP2 ( 35 ) , U0126 ( 1 ) , vanadate ( 25 , 35 ) , VEGF ( 15 , 36 )

Downstream Regulation
Effects of modification on PXN iso2:
activity, induced ( 31 ) , molecular association, regulation ( 27 , 48 ) , phosphorylation ( 1 , 27 ) , protein degradation ( 25 )
Effects of modification on biological processes:
cell cycle regulation ( 1 ) , cell motility, altered ( 25 , 31 , 37 ) , cytoskeletal reorganization ( 25 ) , transcription, altered ( 35 )
Induce interaction with:
CRKL (human) ( 48 ) , Src (human) ( 27 )

References 

1

Sen A, et al. (2010) Paxillin regulates androgen- and epidermal growth factor-induced MAPK signaling and cell proliferation in prostate cancer cells. J Biol Chem 285, 28787-95
20628053   Curated Info

2

Hu Y (2010) CST Curation Set: 8707; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

3

Zhou J (2010) CST Curation Set: 9107; Year: 2010; Biosample/Treatment: cell line, NTERA-2/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-102) Cat#: 9416
Curated Info

4

Zhao Y, et al. (2010) Identification and functional characterization of paxillin as a target of protein tyrosine phosphatase receptor T. Proc Natl Acad Sci U S A 107, 2592-7
20133777   Curated Info

5

Moritz A (2010) CST Curation Set: 9059; Year: 2010; Biosample/Treatment: cell line, HeLa/Peroxide; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

6

Moritz A (2010) CST Curation Set: 9058; Year: 2010; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

7

Ren H (2010) CST Curation Set: 8893; Year: 2010; Biosample/Treatment: tissue, ovary/untreated; Disease: ovarian cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

8

Moritz A, et al. (2010) Akt-RSK-S6 Kinase Signaling Networks Activated by Oncogenic Receptor Tyrosine Kinases. Sci Signal 3, ra64
20736484   Curated Info

9

Gu T (2009) CST Curation Set: 7583; Year: 2009; Biosample/Treatment: liver, hepatocyte/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

10

Heibeck TH, et al. (2009) An extensive survey of tyrosine phosphorylation revealing new sites in human mammary epithelial cells. J Proteome Res 8, 3852-61
19534553   Curated Info

11

Tucker M (2009) CST Curation Set: 6391; Year: 2009; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

12

Tucker M (2009) CST Curation Set: 6390; Year: 2009; Biosample/Treatment: cell line, JHH-4/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

13

Tucker M (2009) CST Curation Set: 6389; Year: 2009; Biosample/Treatment: cell line, SNU-1196/untreated; Disease: bile-duct cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

14

Tucker M (2009) CST Curation Set: 6386; Year: 2009; Biosample/Treatment: cell line, SNU-398/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

15

Birukova AA, Cokic I, Moldobaeva N, Birukov KG (2009) Paxillin is involved in the differential regulation of endothelial barrier by HGF and VEGF. Am J Respir Cell Mol Biol 40, 99-107
18664639   Curated Info

16

Moritz A (2009) CST Curation Set: 5955; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/Gleevec; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

17

Moritz A (2008) CST Curation Set: 5774; Year: 2008; Biosample/Treatment: cell line, NCI-H3255/Iressa; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

18

Moritz A (2008) CST Curation Set: 5775; Year: 2008; Biosample/Treatment: cell line, NCI-H3255/Iressa; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

19

Moritz A (2008) CST Curation Set: 5770; Year: 2008; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

20

Birukova AA, et al. (2008) Cross talk between paxillin and Rac is critical for mediation of barrier-protective effects by oxidized phospholipids. Am J Physiol Lung Cell Mol Physiol 295, L593-602
18676874   Curated Info

21

Rikova K (2008) CST Curation Set: 4434; Year: 2008; Biosample/Treatment: cell line, A549 LKB Dana F/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

22

Ren H (2008) CST Curation Set: 3790; Year: 2008; Biosample/Treatment: cell line, NUGC-2/serum starved; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

23

Ren H (2008) CST Curation Set: 3793; Year: 2008; Biosample/Treatment: cell line, MKN-74/serum starved; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

24

Ren H (2008) CST Curation Set: 3794; Year: 2008; Biosample/Treatment: cell line, SCH/serum starved; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

25

Badowski C, et al. (2008) Paxillin Phosphorylation Controls Invadopodia/Podosomes Spatiotemporal Organization. Mol Biol Cell 19, 633-645
18045996   Curated Info

26

Senyo SE, Koshman YE, Russell B (2007) Stimulus interval, rate and direction differentially regulate phosphorylation for mechanotransduction in neonatal cardiac myocytes. FEBS Lett 581, 4241-7
17698065   Curated Info

27

Doan AT, Huttenlocher A (2007) RACK1 regulates Src activity and modulates paxillin dynamics during cell migration. Exp Cell Res 313, 2667-79
17574549   Curated Info

28

Li Y (2007) CST Curation Set: 2489; Year: 2007; Biosample/Treatment: cell line, NCI-H3255/untreated &'||' Geldanamycin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

29

Li Y (2007) CST Curation Set: 2490; Year: 2007; Biosample/Treatment: cell line, HCC827/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

30

Li Y (2007) CST Curation Set: 2491; Year: 2007; Biosample/Treatment: cell line, HCC827/untreated &'||' Geldanamycin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

31

Lu TJ, et al. (2006) Inhibition of cell migration by autophosphorylated mammalian sterile 20-like kinase 3 (MST3) involves paxillin and protein-tyrosine phosphatase-PEST. J Biol Chem 281, 38405-17
17046825   Curated Info

32

Possemato A (2006) CST Curation Set: 2120; Year: 2006; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

33

Guo A (2006) CST Curation Set: 1937; Year: 2006; Biosample/Treatment: cell line, Hs746T/-; Disease: pancreatic carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

34

Yu J (2006) CST Curation Set: 1748; Year: 2006; Biosample/Treatment: cell line, Kyse520/serum starved; Disease: esophageal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

35

Oh J, et al. (2006) TIMP-2 upregulates RECK expression via dephosphorylation of paxillin tyrosine residues 31 and 118. Oncogene 25, 4230-4
16491114   Curated Info

36

Lu H, Murtagh J, Schwartz EL (2006) The microtubule binding drug laulimalide inhibits vascular endothelial growth factor-induced human endothelial cell migration and is synergistic when combined with docetaxel (taxotere). Mol Pharmacol 69, 1207-15
16415178   Curated Info

37

Azuma K, et al. (2005) Tyrosine phosphorylation of paxillin affects the metastatic potential of human osteosarcoma. Oncogene 24, 4754-64
15870699   Curated Info

38

Sanders MA, Basson MD (2005) p130cas but not paxillin is essential for Caco-2 intestinal epithelial cell spreading and migration on collagen IV. J Biol Chem 280, 23516-22
15817476   Curated Info

39

Moritz A (2005) CST Curation Set: 696; Year: 2005; Biosample/Treatment: cell line, HUVEC/VEGF; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

40

Moritz A (2005) CST Curation Set: 681; Year: 2005; Biosample/Treatment: cell line, HUVEC/VEGF &'||' inhibitor; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

41

Chen HY, et al. (2004) Brk activates rac1 and promotes cell migration and invasion by phosphorylating paxillin. Mol Cell Biol 24, 10558-72
15572663   Curated Info

42

Guo A (2004) CST Curation Set: 412; Year: 2004; Biosample1/Treatment/Isotope: cell line, BxPC-3/EGF &'||' Iressa/L, Biosample2/Treatment/Isotope: cell line, BxPC-3/EGF/H; Disease: pancreatic carcinoma; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

43

Guo A (2004) CST Curation Set: 392; Year: 2004; Biosample1/Treatment/Isotope: cell line, BxPC-3/none/L, Biosample2/Treatment/Isotope: cell line, BxPC-3/EGF/H; Disease: pancreatic carcinoma; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

44

Guo A (2004) CST Curation Set: 393; Year: 2004; Biosample1/Treatment/Isotope: cell line, BxPC-3/EGF/L, Biosample2/Treatment/Isotope: cell line, BxPC-3/EGF/Iressa/H; Disease: pancreatic carcinoma; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

45

Kijima T, et al. (2003) Fibronectin enhances viability and alters cytoskeletal functions (with effects on the phosphatidylinositol 3-kinase pathway) in small cell lung cancer. J Cell Mol Med 7, 157-64
12927054   Curated Info

46

Grace EA, Busciglio J (2003) Aberrant activation of focal adhesion proteins mediates fibrillar amyloid beta-induced neuronal dystrophy. J Neurosci 23, 493-502
12533609   Curated Info

47

Batlle E, et al. (2002) Beta-catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/ephrinB. Cell 111, 251-63
12408869   Curated Info

48

Salgia R, et al. (1995) CRKL links p210BCR/ABL with paxillin in chronic myelogenous leukemia cells. J Biol Chem 270, 29145-50
7493940   Curated Info